Adaptimmune Annual report pursuant to Section 13 and 15(d)

Accrued expenses and other current liabilities

12 Months Ended

Dec. 31, 2023

Note 9 — Accrued expenses and other current liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):


	December 31,		December 31,
	2023		2022
Accrued clinical and development expenditure	$	12,351	$	16,749
Accrued employee expenses		13,226		8,232
VAT payable		1,398		—
Other accrued expenditure		3,277		4,079
Other		51		2,155
	$	30,303	$	31,215